The U.S. Federal Trade Commission Sent Notice Letters To AbbVie, AstraZeneca, Teva And Others Disputing The Accuracy Or Relevance Of Patents Listed In The FDA's Orange Book
Portfolio Pulse from Benzinga Newsdesk
The U.S. Federal Trade Commission (FTC) has sent notice letters to AbbVie, AstraZeneca, Teva, and other pharmaceutical companies, disputing the accuracy or relevance of patents listed in the FDA's Orange Book.
November 07, 2023 | 4:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AbbVie has received a notice from the FTC challenging the accuracy of its patents listed in the FDA's Orange Book.
The FTC's challenge could potentially lead to legal issues for AbbVie, which may negatively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
AstraZeneca has received a notice from the FTC disputing the relevance of its patents listed in the FDA's Orange Book.
The FTC's challenge could potentially lead to legal issues for AstraZeneca, which may negatively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Teva has received a notice from the FTC challenging the accuracy of its patents listed in the FDA's Orange Book.
The FTC's challenge could potentially lead to legal issues for Teva, which may negatively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100